NCT04817540View on ClinicalTrials.gov

Phase II Trial of Anti-HER2 Treatment in HER2-enriched Early Breast Cancer Identified by PAM50 (HER2E-PAM, PAMILIA Study)

PHASE2RecruitingINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

March 30, 2024

Study Completion Date

March 30, 2027

Conditions
HER2 Enriched Subtype Breast Cancer, Herzuma, PAM50 Study
Interventions
DRUG

Herzuma

8mg/kg IVF loading dose at first cycle -\> 6mg/kg IVF at 2,3,4th cycle of each 21 day cycle

Trial Locations (1)

135720

RECRUITING

Gangnam Severance Hospital, Seoul

All Listed Sponsors
lead

Gangnam Severance Hospital

OTHER